Table 2.
Primary and secondary outcomes for bebtelovimab for primary matched cohort.
| Outcome |
Bebtelovimab | Untreated | Adjusted odds ratio (95% confidence interval) | P-value |
|---|---|---|---|---|
| Overall sample | n = 3739 | n = 5423 | – | – |
| All-cause hospitalization within 28-days | 48 (1.3%) | 116 (2.1%) | 0.53 (0.37-0.74) | <0.001 |
| COVID-related hospitalization within 28 days | 38 (1.0%) | 107 (2.0%) | 0.44 (0.30-0.64) | <0.001 |
| All-cause emergency department visit within 28 days | 260 (7.0%) | 276 (5.1%) | 1.35 (1.13-1.62) | 0.001 |
| All-cause mortality within 28 days | 3 (0.1%) | 11 (0.2%) | 0.43 (0.11-1.30) | 0.139 |
| Hospitalized sample | n = 48 | n = 116 | – | – |
| Intensive care unit visit during hospitalization | 6 (12.5%) | 21 (18.1%) | – | – |
All regression models adjusted for age, sex, race/ethnicity, obesity, immunocompromised status, number of comorbidities, insurance status, vaccination status, and subvariant.